Regeneron Pharmaceuticals
REGN
$629.68
-9.82%
Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes treatments for serious medical conditions, including eye diseases, cardiovascular disease, cancer, and inflammation. The company has established itself as a dominant player in the antibody therapeutics space, with a core identity built on its proprietary VelocImmune technology platform and a portfolio anchored by blockbuster drugs like Eylea and Dupixent. The current investor narrative is dominated by the transition of its flagship Eylea franchise amid biosimilar competition, offset by the explosive growth of Dupixent and recent strategic moves, including a high-profile deal with the U.S. administration for drug pricing certainty which trades near-term policy clarity for potential long-term margin pressure.…
REGN
Regeneron Pharmaceuticals
$629.68
Related headlines
Investment Opinion: Should I buy REGN Today?
Rating: Hold. The core thesis is that Regeneron is a high-quality company in a difficult transition, where near-term headwinds are real but the long-term foundation and valuation offer compelling risk/reward for patient investors.
Supporting evidence for this Hold view includes: 1) A deeply discounted forward P/E of 12.96x versus a trailing P/E of 17.92x, implying the market expects a 28% earnings growth rebound. 2) An exceptionally strong balance sheet with a 0.087 debt-to-equity ratio and $4.08B in TTM FCF providing a margin of safety. 3) Robust underlying profitability with gross margins above 84%. 4) Analyst sentiment remains generally bullish, with firms like Guggenheim and JP Morgan maintaining Buy ratings, anchoring a positive long-term view.
The thesis would upgrade to a Buy if the forward P/E compresses further towards 11x on sustained weakness, or if Q1 2026 revenue growth re-accelerates above 5% YoY, signaling the transition is progressing. It would downgrade to a Sell if revenue growth turns negative or if TTM free cash flow shows a sustained decline below $3.5 billion. Currently, the stock appears fairly valued relative to its near-term challenges but undervalued relative to its long-term assets and financial strength.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron is at an inflection point where superb financial strength and a discounted valuation clash with tangible near-term operational headwinds. The neutral stance reflects the high probability (55%) of a muddle-through base case where the stock grinds higher as the Dupixent-for-Eylea transition plays out, but lacks a near-term catalyst for a major breakout. Confidence is medium due to the volatility in quarterly earnings and the uncertain timing of the margin impact from the pricing deal. The stance would upgrade to bullish on confirmation of revenue re-acceleration above 5% or a breakdown to prices near $650, enhancing the margin of safety. It would turn bearish if revenue growth turns negative or free cash flow generation meaningfully deteriorates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $818.58 and implied upside of +30.0% versus the current price.
Average Target
$818.58
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$504 - $819
Analyst target range
Analyst coverage is substantial, with 11 firms providing estimates, indicating strong institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings where firms like Guggenheim, Oppenheimer, JP Morgan, and Truist Securities maintain Buy or Outperform ratings, while others like Morgan Stanley and Wells Fargo are at Equal Weight. The average target price implied by EPS and revenue estimates suggests a consensus view of continued execution, though a specific price target is not provided in the data. The target range, derived from estimated EPS, is wide, with a low of $66.04 and a high of $81.62, signaling meaningful divergence in analyst views on the company's future earnings power. The high end of the range likely assumes successful pipeline execution, sustained Dupixent growth, and minimal disruption from the drug pricing deal, while the low end may factor in more severe Eylea erosion and margin compression. The pattern of recent ratings shows stability, with no downgrades in the provided data from early 2026, suggesting analysts are taking a 'wait-and-see' approach following the Q4 earnings and the administration deal announcement.
Bulls vs Bears: REGN Investment Factors
The evidence presents a tense battle between a deteriorating near-term operational picture and a compelling long-term financial and valuation setup. The bear case currently has stronger near-term evidence, driven by the severe revenue deceleration to 2.51%, sharp technical breakdown, and earnings volatility. However, the bull case is underpinned by a fortress balance sheet, a discounted forward P/E of 12.96x, and the blockbuster potential of Dupixent. The single most important tension in the investment debate is whether Dupixent's explosive growth and pipeline contributions can accelerate fast enough to fully offset the Eylea decline before margin pressure from the pricing deal further dampens earnings. The resolution of this product transition timeline will determine if the current valuation represents a value trap or a strategic entry point.
Bullish
- Strong Dupixent Growth & Pipeline: Dupixent's recent FDA approval for a rare sinus condition expands its blockbuster label, driving revenue diversification away from Eylea. Analyst consensus expects forward EPS of $73.20, implying significant earnings growth from the current trailing EPS of $8.21.
- Exceptional Financial Fortress: The balance sheet is a major strength, with a debt-to-equity ratio of only 0.087 and a current ratio of 4.13, indicating minimal leverage and high liquidity. This is supported by robust TTM free cash flow of $4.08 billion, providing ample resources for R&D and strategic moves.
- Attractive Forward Valuation: The stock trades at a forward P/E of 12.96x, a significant discount to its trailing P/E of 17.92x, signaling the market expects a substantial earnings rebound. This forward multiple is near the lower end of its historical valuation range, suggesting pessimism is priced in.
- Policy Certainty via Admin Deal: The recent deal with the U.S. administration provides near-term clarity on drug pricing and exempts Regeneron from new 100% import tariffs, creating a competitive moat. This mitigates a major regulatory overhang, though at the potential cost of future margin pressure.
Bearish
- Severe Revenue Growth Deceleration: Q4 2025 revenue grew only 2.51% YoY to $3.884 billion, a dramatic slowdown from prior periods, primarily due to Eylea franchise pressure. This raises fundamental questions about the company's ability to sustain its historical growth trajectory during this product transition.
- Pronounced Technical Downtrend: The stock is down 14.62% YTD and 13.06% over the past three months, severely underperforming the S&P 500. It shows a -12.99% relative strength over the past month, breaking below key support and indicating a loss of momentum and investor confidence.
- Earnings Volatility & Margin Pressure: Net income fell sharply from $1.46 billion in Q3 2025 to $844.6 million in Q4 2025, indicating significant quarterly lumpiness. The drug pricing deal, while providing clarity, introduces a long-term risk of margin compression from lower prices and free product giveaways.
- High Dependence on Transition Success: The investment thesis hinges on Dupixent's growth fully offsetting Eylea erosion and pipeline candidates delivering. Any stumble in Dupixent's expansion or clinical setbacks would expose the valuation, which is already discounting a forward earnings recovery.
REGN Technical Analysis
The stock is in a pronounced downtrend, having declined 14.62% year-to-date and 13.06% over the past three months, significantly underperforming the broader market. Currently trading at $698.25, the price sits approximately 15% above its 52-week low of $476.49 but is 15% below its 52-week high of $821.11, positioning it in the lower half of its annual range and suggesting a loss of momentum from earlier highs. Recent momentum is decisively negative, with the stock down 7.39% over the past month, a stark contrast to the S&P 500's 5.6% gain, resulting in severe relative weakness of -12.99%. This sharp one-month decline diverges from the stock's positive 19.36% one-year return, signaling a potential trend reversal or a deep correction as the market reassesses near-term growth prospects. Key technical support is the 52-week low area near $476.49, while immediate resistance lies at the recent breakdown level around $750-$770. A breakdown below $700 could accelerate selling toward the $650 area, while a recovery above $770 is needed to stabilize the trend. With a beta of 0.296, the stock exhibits significantly lower volatility than the market, which historically provided defensive characteristics but has not prevented a sharp recent drawdown of -21.43%.
Beta
0.30
0.30x market volatility
Max Drawdown
-22.5%
Largest decline past year
52-Week Range
$476-$821
Price range past year
Annual Return
+5.9%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -16.1% | +4.0% |
| 3m | -20.6% | +8.2% |
| 6m | -10.4% | +11.5% |
| 1y | +5.9% | +24.3% |
| ytd | -18.9% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Revenue growth has decelerated markedly, with Q4 2025 revenue of $3.884 billion representing only 2.51% year-over-year growth, a significant slowdown from the double-digit growth rates seen in prior periods. Segment data reveals a mixed picture: Collaboration Revenue of $1.971 billion and Product Revenue of $1.675 billion, with the slower growth primarily attributed to pressures on the Eylea franchise. This deceleration raises concerns about the company's ability to sustain its historical growth trajectory as it navigates product transitions. Profitability remains robust but is showing signs of compression; net income for Q4 2025 was $844.6 million, yielding a net margin of 21.74%, while the gross margin was a healthy 84.95%. However, comparing sequential quarters shows volatility, with net income down significantly from $1.46 billion in Q3 2025, indicating potential lumpiness in earnings and margin pressure from the recent drug pricing agreement. The balance sheet and cash flow position are exceptionally strong, underpinning the investment case. The company boasts a debt-to-equity ratio of just 0.087, indicating minimal financial leverage, and a robust current ratio of 4.13. Trailing twelve-month free cash flow is a substantial $4.08 billion, providing ample internal resources to fund R&D, share repurchases, and business development without relying on external financing, which is a key pillar of financial stability.
Quarterly Revenue
$3.9B
2025-12
Revenue YoY Growth
+0.02%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$4.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 17.92x, while the forward PE is notably lower at 12.96x. This significant gap implies the market expects a substantial rebound in earnings growth over the next twelve months, likely pricing in contributions from Dupixent's expansion and pipeline catalysts. Compared to the broader biotechnology sector, Regeneron's trailing PE of 17.92x is at a discount to many high-growth peers but is likely in line with large-cap biotech averages, reflecting its more mature profile and near-term growth headwinds. The discount to its own forward multiple suggests the stock is not priced for perfection, leaving room for multiple expansion if execution improves. Historically, the current trailing PE of 17.92x sits near the lower end of its own range over the past several years, as evidenced by historical ratios showing PEs above 20x and even 30x during peak growth phases in 2021-2022. Trading near the bottom of its historical valuation band suggests the market has priced in significant pessimism, potentially offering a value opportunity if the company can successfully navigate its product cycle transition and deliver on its forward earnings estimates.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 5x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on growth sustainability and margin compression. Revenue growth has decelerated sharply to 2.51% YoY, raising the risk that the company's valuation, which implies a forward earnings rebound, is too optimistic. Furthermore, the recent drug pricing deal trades regulatory certainty for potential long-term margin pressure, which could erode the robust 84.95% gross margin. Earnings have also shown high volatility, with Q4 net income down 42% sequentially from Q3, indicating lumpiness that complicates forecasting.
Market & Competitive Risks include valuation compression and competitive disruption. Despite the discounted forward P/E of 12.96x, the elevated PEG ratio of 3.38 suggests the stock is priced for growth that isn't materializing, leaving it vulnerable to derating. Competitively, biosimilar pressure on Eylea is a realized threat, while rivals like AstraZeneca are advancing in adjacent markets like COPD. The stock's low beta of 0.296 offers little defense, as evidenced by its -21.43% max drawdown and severe underperformance versus the market.
Worst-Case Scenario involves a 'perfect storm' where Eylea erosion accelerates faster than expected, Dupixent growth stalls due to competition or market saturation, and the drug pricing deal materially crimps profitability sooner than anticipated. This could lead to consecutive earnings misses, analyst downgrades, and a full derating to a value multiple. The realistic downside could see the stock re-test its 52-week low of $476.49, representing a potential loss of approximately -32% from the current price of $698.25. A more probable severe bear case might target the $550-$600 range, a -12% to -21% decline.
FAQ
The key risks are, in order of severity: 1) Product Transition Risk: Failure of Dupixent growth to fully offset Eylea erosion, as evidenced by the sharp revenue deceleration to 2.51% YoY. 2) Margin Compression Risk: The recent drug pricing deal could pressure long-term profitability from the current high gross margin of 84.95%. 3) Valuation Risk: The high PEG ratio of 3.38 leaves the stock vulnerable to multiple compression if growth doesn't re-accelerate. 4) Competitive/Regulatory Risk: Biosimilar competition for Eylea is ongoing, and the broader drug pricing environment remains a headwind despite the recent deal.
The 12-month forecast is a range of outcomes centered on a gradual recovery. The base case (55% probability) sees the stock trading between $730 and $820 as Dupixent growth offsets Eylea declines, leading to low-single-digit revenue growth and stable margins. The bull case (30% probability) targets $821 to $900 on faster-than-expected Dupixent growth and pipeline successes. The bear case (15% probability) could see a re-test of the $476 to $650 range if the transition falters and margins contract. The most likely scenario is the base case, which assumes successful execution of the current product transition plan without major setbacks.
REGN appears fairly valued to slightly undervalued based on forward earnings, but the near-term growth disconnect creates risk. The forward P/E of 12.96x is a 28% discount to the trailing P/E of 17.92x, implying the market expects a significant earnings rebound. Compared to its own history, trading near the lower end of its valuation range suggests pessimism is priced in. However, the elevated PEG ratio of 3.38 indicates it is still priced for growth that isn't currently visible. The valuation implies the market expects Dupixent to drive a sharp earnings recovery; if that occurs, the stock is undervalued. If not, it could be fairly valued or overvalued.
REGN is a good buy for long-term, patient investors who can tolerate near-term volatility, but not for those seeking short-term gains. The stock offers a compelling combination of a fortress balance sheet (debt-to-equity 0.087), strong cash flow ($4.08B TTM FCF), and a discounted forward P/E of 12.96x. However, with revenue growth decelerated to 2.51% and the stock in a technical downtrend, immediate upside is limited. The biggest risk is that the Eylea-to-Dupixent transition takes longer or is less profitable than expected. It's a good buy on further weakness for a multi-year holding period.
REGN is unequivocally suitable for a long-term investment horizon, with a suggested minimum holding period of 3-5 years. The company's transition from Eylea to Dupixent and its pipeline is a multi-year story. Its low beta of 0.296 indicates lower volatility than the market, which is more characteristic of a long-term holding. The stock does not pay a meaningful dividend (yield 0.46%), so it is not an income play. Short-term trading is challenged by the lack of near-term catalysts, recent negative momentum (-7.39% over 1 month), and earnings volatility. Long-term investors can look through the quarterly noise to the underlying financial strength and growth pipeline.